OSE Immunotherapeutics SA

DB:6OP Stock Report

Market Cap: €153.6m

OSE Immunotherapeutics Management

Management criteria checks 3/4

OSE Immunotherapeutics' CEO is Nicolas Poirier, appointed in Jan 2016, has a tenure of 8.92 years. total yearly compensation is €440.10K, comprised of 68.2% salary and 31.8% bonuses, including company stock and options. directly owns 1.58% of the company’s shares, worth €2.42M. The average tenure of the management team and the board of directors is 6.5 years and 2.5 years respectively.

Key information

Nicolas Poirier

Chief executive officer

€440.1k

Total compensation

CEO salary percentage68.2%
CEO tenure8.9yrs
CEO ownership1.6%
Management average tenure6.5yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nicolas Poirier's remuneration changed compared to OSE Immunotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

€46m

Mar 31 2024n/an/a

€12m

Dec 31 2023€440k€300k

-€23m

Sep 30 2023n/an/a

-€25m

Jun 30 2023n/an/a

-€28m

Mar 31 2023n/an/a

-€23m

Dec 31 2022€1mn/a

-€18m

Sep 30 2022n/an/a

-€13m

Jun 30 2022n/an/a

-€7m

Mar 31 2022n/an/a

-€12m

Dec 31 2021€18kn/a

-€17m

Sep 30 2021n/an/a

-€21m

Jun 30 2021n/an/a

-€25m

Mar 31 2021n/an/a

-€21m

Dec 31 2020€19kn/a

-€17m

Sep 30 2020n/an/a

-€12m

Jun 30 2020n/an/a

-€8m

Mar 31 2020n/an/a

-€6m

Dec 31 2019€9kn/a

-€5m

Compensation vs Market: Nicolas's total compensation ($USD459.20K) is below average for companies of similar size in the German market ($USD902.55K).

Compensation vs Earnings: Nicolas's compensation has been consistent with company performance over the past year.

CEO

Nicolas Poirier (42 yo)

8.9yrs

Tenure

€440,100

Compensation

Dr. Nicolas Poirier, PhD, has been the Scientific Director of OSE Immunotherapeutics SA since 2016 and serves as its Director from June 26, 2019 and also serves as its General Director & Chief Executive Of...

Leadership Team

NamePositionTenureCompensationOwnership
Nicolas Poirier
General Director8.9yrs€440.10k1.58%
€ 2.4m
Anne-Marie Costantini
Founder & Director of Development & Strategy12.9yrs€412.50k9.23%
€ 14.2m
Anne-Laure Autret-Cornet
CFO, Administrative & Financial Director and Employee Shareholder Representative Director8.6yrsno datano data
Alexis Peyroles
Consultant2.9yrs€586.59kno data
Alain Chatelin
Medical Directorno datano datano data
Bérangère Vasseur
Chief Medical Officer Immuno-Oncology6.9yrsno datano data
Julien Perrier
Chief Commercial Officer6yrsno datano data
Linda Lebon
Chief Regulatory Officer3yrsno datano data
Silvia Comis
Head of Clinical Development3yrsno datano data
Jean-Jacques Mention
Chief Business Officerno datano datano data

6.5yrs

Average Tenure

54yo

Average Age

Experienced Management: 6OP's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicolas Poirier
General Director5.5yrs€440.10k1.58%
€ 2.4m
Anne-Laure Autret-Cornet
CFO, Administrative & Financial Director and Employee Shareholder Representative Director1.5yrsno datano data
Maryvonne Hiance
Vice Chairwoman8.6yrs€25.71k1.95%
€ 3.0m
Bernard Malissen
Member of Scientific Advisory Board2.5yrsno datano data
Sophie Brouard
Director of External Affairs & Member of the Scientific Advisory Board2.5yrs€25.71kno data
Charles Serhan
Member of Scientific Advisory Board2.5yrsno datano data
Brigitte Dreno
Independent Director7.5yrs€21.43kno data
Didier Hoch
Independent Chairman of the Board of Directors8.6yrs€28.57kno data
Wolf-Herve Fridman
Chairman of the Scientific Board11.1yrsno datano data
Jennifer Wargo
Member of Scientific Advisory Board2.5yrsno datano data
Myriam Merad
Member of Scientific Advisory Board2.5yrsno datano data
Eric Leire
Independent Director1.5yrs€15.00kno data

2.5yrs

Average Tenure

68yo

Average Age

Experienced Board: 6OP's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OSE Immunotherapeutics SA is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olga SmolentsevaBryan Garnier & Co
David SeynnaeveDegroof Petercam
Laura RobaDegroof Petercam